LONGITUDINAL ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 RNA IN BREAST MILK AND OF ITS RELATIONSHIP TO INFANT INFECTION AND MATERNAL DISEASE
Purpose of the Study. Transmission of human immunodeficiency virus (HIV) via breastfeeding may occur throughout lactation. In developing countries, where Ͼ90% of HIV-exposed children live, safe alternatives to breastfeeding are not available. An understanding of the dynamics of breast milk virus levels and the correlation of breast milk virus levels with mother-to-child transmission is essential for the development of effective interventions.
Methods. A total of 648 breast milk samples were collected from 275 women enrolled in a clinical trial in Nairobi, Kenya, between 1992 and 1998 . Antiretroviral regimens were not available to the women at the time of the study. Breast milk samples were analyzed for virus levels, and infants were monitored for up to 2 years, for assessment of HIV transmission.
Results. The average duration of breastfeeding was 21 months. Of the 275 women, 70 transmitted HIV to their infants and 205 did not. Greater maternal plasma viral loads, lower maternal CD4 ϩ T cell counts, and detection of HIV DNA in maternal genital secretions were significantly associated with elevated breast milk HIV RNA levels. The median viral load in early milk was significantly greater than that in breast milk collected 14 days after delivery. Breastfeeding mothers who transmitted HIV had significantly higher breast milk HIV RNA levels and more consistent viral shedding, compared with mothers who did not transmit HIV.
Conclusions. The risk of infant infection through breastfeeding was increased by higher levels of virus in breast milk; levels were highest early after delivery.
Reviewer's Comments. In developing countries, the rate of perinatal HIV transmission approaches 50%. This is dramatically higher than the 20% to 25% rate of transmission that was noted in developed countries before the initiation of perinatal antiretroviral therapy. It is now clear that breastfeeding is a significant factor in the transmission of HIV from mother to child and may be responsible for Ն30% of transmissions in developing countries. Unfortunately, safe alternatives to breastfeeding do not exist for most HIV-positive women. Provision of effective perinatal antiretroviral therapy, combined with safe alternative feeding methods, is required to significantly affect the extraordinary rate of HIV disease among children in the developing world.
Methods. Activation of T cells requires stimulation of the antigen-specific T-cell receptor and ligation of coreceptors on the T cell surface. One coreceptor on the surface of T cells is CD27, a member of the tumor necrosis factor receptor family. CD70 is the ligand for CD27. The investigators generated a CD70-transgenic mouse model in which CD70 was constitutively expressed on B cells, resulting in chronic T cell activation in the absence of viral infection.
Results. These mice demonstrated progressive conversion of naïve T cells into effector-memory cells. The end result was depletion of naïve T cells from lymph nodes and spleen. Despite this hyperactive immune response, CD70-transgenic mice died as a result of Pneumocystis carinii pneumonia, which is an acquired immunodeficiency syndrome-defining condition among human patients infected with HIV.
Conclusions. Constant activation of T cells via CD27-CD70 interactions, as may occur among human subjects during chronic active viral infections, may result in exhaustion of the T cell pool and the development of fatal immunodeficiency.
Reviewer's Comments. It has been unclear how T cell loss occurs during HIV infection. Some T cells are undoubtedly killed by infection with HIV. However, the magnitude of the T cell loss is not explained by this pathway. Very early in the HIV epidemic, it appeared that chronic immune activation was a hallmark of HIV disease. Was the immune activation a cause of T cell loss or simply the effect of chronic viral infection? In other primates, chronic infection with retroviruses may not cause any detectable immune dysfunction if immune activation is not induced. This study clearly demonstrated that immune activation alone might be sufficient to induce T cell deficiency. If the virus cannot be eradicated, then perhaps induction of immunologic tolerance to it may be the next best thing. 
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Purpose of the Study. There is renewed interest in the use of smallpox vaccine, because of the potential for a bioterrorist attack. One obvious question relates to the current status of people who have been vaccinated in the past. This study sought to evaluate the use of diluted vaccinia virus for vaccination of previously vaccinated (nonnaive) participants.
Study Population. Eighty nonnaive participants, 32 to 60 years of age, were randomized to receive either undiluted or diluted (1:3.2, 1:10, or 1:32) doses of smallpox vaccine, in a single-blinded study. A comparison group of 10 vaccinia-naive participants, 18 to 31 years of age, received undiluted vaccine.
Methods. Participants were enrolled between April 1 and May 15, 2002, at the National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Unit at St Louis University (St Louis, MO). Smallpox vaccine was administered through scarification, using 15 skin punctures in the deltoid region of the arm. Outcome measures included the presence of a major reaction, defined as a vesicular or pustular lesion or area of palpable induration surrounding a central lesion, after vaccination, measures of viral shedding, and antibody titers.
Results. Initial vaccination resulted in a major reaction for 64 of 80 nonnaive participants. Ninety-five percent of nonnaive participants had major reactions in the undiluted group, 90% in the 1:3.2 dilution group, 81% in the 1:10 dilution group, and 52.6% in the 1:32 dilution group. All of the vaccinia-naive participants (n ϭ 10) experienced major reactions. Compared with vaccinia-naive participants, nonnaive participants had significantly smaller skin lesions (P ϭ .04) and a significantly lower incidence of fever (P ϭ .02). Preexisting antibody was present in 76 of 80 nonnaive participants. Antibody responses were significantly greater and occurred more rapidly among the nonnaive participants, compared with the vaccinia-naive participants (P ϭ .002 for day 28 and P ϭ .003 for 6 months). Vaccinia-naive participants shed virus from the vaccination site 2 to 6 days longer and had significantly higher mean peak viral titers, compared with the nonnaive participants (P ϭ .002).
Conclusions. Previously vaccinated persons could be successfully revaccinated with diluted (Յ1:10) smallpox vaccine. Fewer adverse reactions were observed in this study among nonnaive participants, compared with vaccinia-naive participants, which might be attributable to immunologic memory.
Reviewer's Comments. This is an excellent practical study addressing an important issue. Although we hope that widespread smallpox vaccination will not be necessary, these data should be useful for the design of whatever program might be necessary. Purpose of the Study. To determine whether pneumococcal conjugate vaccine can prevent acute otitis media (AOM) among older children who have experienced previous episodes of AOM.
Study Population. A total of 383 children (1-7 years of age) with Ն2 episodes of AOM in the year before study entry were studied.
Methods. Children recruited from a Netherlands general hospital and tertiary care hospital were randomized to receive either 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide or hepatitis A or B vaccines, in a double-blind trial. The randomization was stratified into 4 groups according to age (12-24 months versus 25-84 months) and the number of prior AOM episodes (from parental reports, with physician confirmation) (2 or 3 episodes vs Ն4 episodes). All children were monitored, via parental diaries and clinical examinations, for 18 months for the recurrence of AOM. Cultures of middle ear fluid and nasopharyngeal swabs were performed to assess the association of pneumococcal serotypes with AOM after vaccination.
Results. Of the 383 children enrolled, 190 received pneumococcal vaccinations and 193 received control hepatitis vaccinations. A total of 474 episodes of AOM were diagnosed during the follow-up period after the final vaccination, with 275 recorded for 107 of the 186 children in the pneumococcal vaccine group (58%) and 200 recorded
